Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Pathway, Not A Shortcut: 505(b)(2) NDAs Have Longer Reviews Than NMEs

Executive Summary

US FDA's argument that its review resources favor novelty/medical advances could be buttressed by Tufts Center for the Study of Drug Development analysis of (less novel) approvals using the streamlined 505(b)(2) NDA pathway.

Advertisement

Related Content

Keeping Track: US FDA Refuses To File Acorda, SteadyMed NDAs
Emflaza's 505(b)(2) Pathway Review: Rare, But With Precedent
Novel Approvals Were Fewer But Faster At US FDA In 2016
Big Pharma's Winning Formula: Many Approvals, Narrow Markets
Once More, With Statistics: FDA Defends Division Productivity Differences

Topics

Advertisement
UsernamePublicRestriction

Register

PS120249

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel